Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: Review of clinical features and antibody specificities

Journal of Neuroscience Research

Volumn 80, Issue 1, 2005, Pages 1-17

  Ariga, Toshio ^a   Yu, Robert K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antiglycolipid antibodies; Glycosphingolipids; Guillain Barr syndrome

Indexed keywords

ANTIBODY; BETA INTERFERON; EPITOPE; GANGLIOSIDE GM1 ANTIBODY; GLYCOLIPID ANTIBODY; GLYCOSPHINGOLIPID ANTIBODY; IMMUNOGLOBULIN; OLIGOSACCHARIDE; POLYVINYL ALCOHOL; STEROID; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ASEPTIC MENINGITIS; BULBAR PARALYSIS; CELLULAR IMMUNITY; CLINICAL FEATURE; DEMYELINATING NEUROPATHY; DRUG TARGETING; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOADSORPTION; INTESTINE INFECTION; NEUROMUSCULAR BLOCKING; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PERIPHERAL NERVE; PHOTOPHOBIA; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SERODIAGNOSIS; STEROID THERAPY;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 17744396351     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20395     Document Type: Review

References (147)

1. Adair J, Rose J, Alderson K. 1993. Inflammatory polyneuropathy after heart transplantation. Its association with antibodies to asialo-GM1 and sulfatide. Transplantation 56:1597-1599.
2. Ang CW, Koga M, Jacobs BC, Yuki N, van der Meche FGA, van Doorn PA. 2001. Differential immune response to gangliosides in Gullain-Barré syndrome patients from Japan and The Netherlands. J Neuroimmunol 121:83-87.
3. Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, De Klerk MA, Tio-Gillen AP, Van den Braak Jacobs BC, Van Doorn PA. 2002. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fischer patients. Infect Immun 70:1202-1208.
4. Ang CW, Jacobs BC, Laman JD. 2004. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 25:61-66.
5. Apostrolski S, Sadiq SA, Hays A, Corbo M, Suturkova-Milosevic L, Chaliff P, Stefansson K, LeBaron RG, Ruoslahti E, Hays AP. 1994. Identification of Gal(β1-3)GalNAc bearing glycoproteins at the nodes of Ranvier in peripheral nerve. J Neurosci Res 38:134-141.
6. Arasaki K, Kusunoki S, Kudo N, Kanazawa I. 1993. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve 16:587-593.
7. Ariga T, Kohriyama T, Freddo L, Latov N, Saito M, Kon K, Ando S, Suzuki M, Hemling ME, Rinhart KL, Kusunoki S, Yu RK. 1987. Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem 262:848-853.
8. Ariga T, Miyatake T, Yu RK. 2001. Recent studies on roles of antiglycosphingolipids in the pathogenesis of neurological disorders. J Neurosci Res 65:363-370.
9. Asbury AK. 2000. New concepts of Guillain Barre syndrome. J Child Neurol 15:183-191.
10. Aspinall GO, McDonald AG, Pang H, Kurianczyk LA, Penner H. 1994. lipopolysaccharides of Campylobacter jejuni serotype O:19; structure of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 33:241-249.
11. Benatar M, Willison HJ, Vincent A. 1999. Immune-mediated peripheral neuropathies and voltage-gated sodium channels. Muscle Nerve 22:108-110.
12. Bjorkander J, Hammarstrom L, Smith CL, Buckley RH, Cunningham-Rundles C, Hanson LA. 1987. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7:8-15.
13. Bowes T, Wagner ER, Boffey J, Nicholl D, Cochrane L, Benboubetra M, Conner J, Furukawa K, Furukawa K, Willison HJ. 2002. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Infect Immun 70: 5008-5018.
14. + channel blocking factor in the cerebrospinal fluid. Pflugers Arch 421:552-557.
15. Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J. 1998. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann Neurol 44: 913-922.
16. Buchwald B, Bufler J, Carpo M, Heidenreich F, Pitz R, Dudel J, Nobile-Orazio E, Toyka KV. 2001. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 56:67-74.
17. Byrne MC, Sbaschnig-Agler M, Aquino DA, Sclafani JR, Ledeen RW. 1985. Procedure for isolation of gangliosides in high yield and purity: simultaneous isolation of neutral glycosphingolipids. Anal Biochem 148: 163-173.
18. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. 1992. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31:677-679.
19. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. 1993. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller-Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 43:1911-1917.
20. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. 1997. Ganglioside composition of the human cranial nerves with special reference to phathophysiology of Miller Fisher syndrome. Brain Res 745:32-36.
21. Cosi V, Lombardi M, Piccolo G, Erbetta A. 1991. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurorol Scand 84:81-84.
22. Dasgupta S, van Halbeek H, Hogan EL. 1992. Ganglio-N-tetra-osylceramide (GA1) of bovine and human brain. Molecular characterization and presence in myelin. FEBS Lett 301:141-144.
23. Dasgupta S, Li D, Yu RK. 2004. Lack of apparent neurological abnormalities in rabbits sensitized by gangliosides. Neurochem Res 29:214-215.
24. Deisenhammer F, Keir G, Pfausler B, Thompson EJ. 1996. Affinity of anti-GM1 antibodies in Guillain-Barré syndrome patients. J Neuroimmunol 66:85-93.
25. Dilley A, Gregson NA, Hadden RDM, Smith KJ. 2003. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barré syndrome. J Neuroimmunol 139:133-140.
26. Fidelio G, Ariga T, Maggio B. 1991. Molecular parameters of gangliosides in monolayers: comparative evalution of suitable purification procedures. J Biochem (Tokyo) 110:12-16.
27. Finsterer J, Derfler K. 1999. Immunoadsorption in multifocal neuropathy. J Immunother 32:441-442.
28. Fredman P. 1998. The role of anti-glycolipid antibodies in neurological disorders. Ann N Y Acad Sci 845:341-352.
29. Fredman P, Lycke J, Andersen O, Vrethem M, Ernerudth J, Svennerholm L. 1993. Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope. J Neurol 240:381-387.
30. Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, Li CY, Griffin JW, Schnaar RL, Sheikh KA. 2002. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 125:2491-2506.
31. Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ. 1999. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104: 697-708.
32. Gregson NA, Jones D, Thomas PK, Willison HJ. 1991. Acute motor neuropathy with antibodies to GM1 ganglioside. J Neurol 238:447-451.
33. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR. 1995. Guillain-Barré syndrome in northern China. The spectrum of neurothological changes in clinically defined cases. Brain 118:577-595.
34. Hadden RD, Gregson NA, Gold R, Willison HJ, Hughes RA. 2001. Guillain-Barré syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. J Neuroimmunol 119: 306-316.
35. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhann GM, Asbury AK, Griffin JW. 1996. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 40:635-644.
36. Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. 1999. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol 45:758-768.
37. Ho TW, McKhann GM, Griffin JW. 1998. Human autoimmune neuropathies. Annu Rev Neurosci 21:187-226.
38. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. 1978. Controlled trial of prednisolone in acute polyneuropathy. Lancet 2:750-753.
39. Ifergane G, Bersudsky M, Kachko L, Wirguin I. 2003. Induction of conduction block by Campylobacter jejuni lipopolysaccharides and focal neural insult. J Neurol Sci 213:11-14.
40. Ilyas AA, Mithen FA, Dalakas MC, Wargo M, Chen Z-W, Bielory L, Cooks SD. 1991. Antibodies to sulfated glycolipids in Guillain-Barré syndrome. J Neurol Sci 105:108-117.
41. Ilyas AA, Chen ZW, Cook SD, Mithen FA, Singhal BS. 2001. Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain-Barré syndrome. Res Commun Mol Pathol Pharmacol 109:115-123.
42. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H. 1996. Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection. J Neuroimmunol 68:19-26.
43. Jacobs BC, van Doorn PA, Schmitz PI, Tio-Gillen AP, Herbrink P, Visser LH, Hooijkass H, van der Meche FG. 1996. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 40: 181-187.
44. Jacobs BC, van Doorn PA, Groeneveld JH, Tio-Gillen AP, van der Meche FG. 1997. Cytomegalovirus infections and anti-GM2 antibodies in Guillain- Barré syndrome. J Neurol Neurosurg Psychiatry 62:641-643.
45. Jacobs BC, Rothbarth PH, van der Meche FGA, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA. 1998. The spectrum of antecedent infections in Guillain-Barre syndrome. A case-control study. Neurology 51: 1110-1105.
46. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. 2003. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126:2220-2234.
47. Jimenez C, Rosenow F, Grieb P, Haupt WF, Borberg H. 1993. Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barré syndrome. Transfus Sci 14:9-11.
48. Jungalwala FB. 1994. Expression and biological functions of sulfoglucuronyl glycolipids (SGGLs) in the nervous system-a review. Neurochem Res 19:945-957.
49. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2000. Guillain-Barré syndrome with antibody to a ganglioside, N-acetyl-galactosaminyl GD1a. Brain 123:116-124.
50. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2001. Guillain-Barre syndrome with IgM antibody to the ganglioside GalNAc-GD1a. J Neuroimmunol 113:260-267.
51. Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I. 2003. GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody. Neurology 61:465-470.
52. Kanda T, Yoshino H, Ariga T, Yamawaki M, Yu RK. 1994. Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy. J Cell Biol 126:235-246.
53. Kanda T, Iwasaki T, Yamawaki M, Tai T, Mizusawa H. 2000. Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model. Neurology 55:585-687.
54. Kanda T, Yamawaki M, Mizusawa H. 2003. Sera from Guillain-Barré patients enhance leakage in blood-nerve barrier model. Neurology 60: 301-306.
55. Kieseier BC, Kiefer R, Gold R, Hermmer B, Willison HJ, Hartung HP. 2004. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131-156.
56. Kitazawa K, Tagawa Y, Honda A, Yuki N. 1998. Guillain-Barré syndrome associated with IgG anti-GM1b antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 156:99-101.
57. Koga M, Yuki N, Ariga T, Morimatsu M, Hirata K. 1998. Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome? J Neuroimmunol 86: 74-79.
58. Koga M, Yuki N, Hirata K. 1999a. Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Neuroimmunol 96:245-250.
59. Koga M, Yuki N, Hirata K. 1999b. Antiganglioside antibody in patients with Guillain-Barré syndrome who show bulbar palsy as an initial symptom. J Neurol Neurosurg Psychiatry 66:513-516.
60. Koga M, Yuki N, Ariga T, Hirata K. 1999c. Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndrome: their association with cranial nerve dysfunction. J Neurol Sci 64:50-55.
61. Kohriyama T, Ariga T, Yu RK. 1988. Preparation and characterization of antibodies against a sulfated glucuronic acid-containing glycosphingolipid. J Neurochem 51:869-877.
62. Kornberg AJ, Pestronk A, Bieser K, Ho TW, McKhann GM, Wu HS, Jiang Z. 1994. The clinical correlates of high-titer IgG anti-GM1 antibodies. Ann Neurol 35:234-237.
63. Krarup C. 2002. Nerve conduction studies in selected peripheral nerve disorders. Curr Opin Neurol 15:579-593.
64. Kusunoki S, Tsuji S, Nagai Y. 1985. Ganglio-N-tetraosylceramide (asialo-GM1), an antigen common to the brain and immune system: its localization in myelin. Brain Res 334:117-124.
65. Kusunoki S, Chiba A, Kon K, Ando S, Arisawa K, Tate A, Kanazawa I. 1994. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 35:570-576.
66. Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. 1995. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 18:409-413.
67. Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. 1996a. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39:424-431.
68. Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. 1996b GM1b is a new number of antigen for serum antibody in Guillain-Barré syndrome. Neurology 47:237-242.
69. Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, Hitoshi S. Kanazawa I. 1997. Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve 20:840-845.
70. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M. 1998. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 44:202-208.
71. Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, Kanesaka T, Hattori T, Yuki N. 2004. Does Campylobacter jejuni infection elicit "demyelination" Guillain-Barré syndrome? Neurology 63:529-533.
72. Li CY, Xue Tian WQ, Liu RC, Yang C. 1996. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 61:279-284.
73. Llinas R, Sugimori M, Cherksey BD, Smith RG, Delbono O, Stefani E, Appel S. 1993. IgG from amyotrophic lateral sclerosis patients increases current through P-type calcium channels in mammalian cerebella Purkinje cells and in isolated channel protein in lipid bilayer. Proc Natl Acad Sci U S A 90:11743-11747.
74. Lopez H, Lardone RD, Irazoqui FJ, Maccioni M, Nores GA. 2002. The origin of anti-GM1 antibodies in neuropathies: the "binding bite drift" hypothesis. Neurochem Res 27:687-695.
75. Maeda Y, Brosnan CF, Miyatani N, Yu RK. 1991. Preliminary studies on the sensitization of Lewis rats with sulfated glucuronyl paragloboside. Brain Res 541:257-264.
76. Malik U, Oleksowicz L, Latov N, Cardo LJ. 1996. Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 39:136-139.
77. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA, the Guillain-Barré Study Group. 1988. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347-353.
78. Moran AP, Prendergast MM, Hogan EL. 2002. Sialosyl-galactose: a common denominator of Guillain-Barré and related disorders? J Neurol Sci 196:1-7.
79. Miyatani N, Kohriyama T, Maeda Y, Yu RK. 1990. Sulfoglucruonyl paragloboside in rat bran microvessels. J Neurochem 55:577-582.
80. Muchnik S, Losavio A, Lorenzo SD. 2002. Effect of amyotrophic lateral sclerosis serum on calcium channels related to spontaneous acetylcholine release. Clin Neurophysiol 113:1066-1071.
81. Nachamkin I, Liu J, Li M, Ung H, Morgan AP, Prendergast MM, Sheikh K. 2002. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses an GD(1a)-like epitope. Infect Immun 70:5299-5303.
82. Nagai Y, Momoi T, Saito M, Mitsuzawa E, Ohtani S. 1976. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett 2:107-111.
83. Niebroj-Dobosz I, Jamrozik Z, Janik P, Hausmanowa-Petrusewicz I, Kwiecinski H. 1999. Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol Scand 100:238-243.
84. Nishmura M, Saida T, Kuroki S, Kawabata T, Obayashi H, Saida K, Uchiyama T. 1996. Post-infections encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 140:91-95.
85. Nobile-Ozazio E. 2001. Multifocal motor neuropathy. J Neuroimmunol 115:4-18.
86. Nobile-Orazio E, Carpo M, Legname G, Meucci N, Sonnino S, Scarilato G. 1990. Anti-GM1 IgM antibodies in motor neuron disease and neuropathy. Neurology 40:1747-1750.
87. Nobile-Ozazio E, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, Mangoni A, Scarilato G. 1992. Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci 109:200-206.
88. Odaka M, Yuki N, Hirata K. 2001. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 70:50-55.
89. Ogawa-Goto K, Kubota K, Kurotani A, Abe T. 1994. Antibodies against sulfated glycosphingolipids of peripheral nerve myelin detected in patients with human cytomegalovirus infection. J Neuroimmunol 55:55-60.
90. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. 2000. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48:624-631.
91. O'Hanlon GM, Paterson GJ, Wilson G, Doyle D, McHardie O, Willison HJ. 1996. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J Neuropathol Exp Neurol 55:184-195.
92. O'Hanlon GM, Plomp JJ, Chakrabarti M, Morrison I, Wagner ER, Goodyear CS, Yin X, Trapp BD, Cornner BB, Molenaar PC, Stewart S, Rowan EG, Willison HJ. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124:893-906.
93. Ortiz N, Rosa R, Gallardo E, Illa L, Tomas J, Aubry J, Sabatez M, Santafe M. 2001. IgM monoclonal antibody against terminal moiety of GM2, GalNAc-GD1a and GalNAc-GM1b from a pure motor chronic demyelinating polyneuropathy patient: effects on neurotransmitter release. J Neuroimmunol 119:114-123.
94. Prendergast MM, Moran AP. 2000. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J Endotoxin Res 6:341-359.
95. Qiu JX, Marcus DM. 1999. Use of peptide ligands to analyze the fine specificity of antibodies against asialo GM1. J Neuroimmunol 100:58-63.
96. Quattrini A, Lorenzetti I, Sciorati C, Corbo M, Previtali SC, Feltri ML, Canal N, Wrabetz L, Nemni R, Clementi E. 2001. Human IgM anti-GM1 autoantibodies modulate intracellular calcium homeostasis in neuroblastoma cells. J Neuroimmunol 114:213-219.
97. Romano JG, Rotta FT, Potter P, Rosenfeld Y, Santibanez R, Rocha B, Bradley WG. 1998. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 21:1327-1330.
98. Saez-Torres I, Diaz-Villoslada P, Martinez-Caceres E, Ferrer I, Montalban X. 1998. Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. J Neuroimmunol 84:24-29.
99. Saida T, Saida K, Dorfman SH, Silberberg DH, Sumner A, Manning MC, Lisak RP, Brown MJ. 1979. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 204:1103-1106.
100. Sawada K, Sakurami T, Imura H, Iwamori M, Nagai Y. 1980. Anti-asialo-GM1 antibody in sera from patients with Graves' disease and Hashimoto's thyroditis. Lancet 2:198.
101. Scherer SS. 1996. Molecular specializations at nodes and paranodes in peripheral nerve. Microsc Res Techniq 34:452-461.
102. Sheikh KA, Nachamkin I, Ho TW, Li C-Y, McKhann GM, Griffin JW. 1995. Penner's serotype 19 Campylobacter jejuni lipopolysaccharide isolated from a patient with acute motor axonal neuropathy bears L2/HNK1 and GM1 epitopes [abstract]. Ann Neurol 38:350.
103. Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW. 1999. The distribution of ganglioside-like moieties in peripheral nerves. Brain 122:449-460.
104. Sheikh KA, Zhang G, Gong Y, Schnaar RL, Griffin JW. 2004. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 56:228-239.
105. Simon-Haldi M, Mantei N, Franke J, Voshol H, Schachner M. 2002. Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope. J Neurochem 83:1380-1388.
106. Suzuki K, Yuki N, Hirata K. 2001. Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol 112:181-187.
107. Suzuki K, Yuki N, Hirata K, Kuwabara S. 2002. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. J Neurol Sci 195: 145-148.
108. Suzuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K, Yuki N. 2003. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann Neurol 54:383-388.
109. Svennerholm L. 1964. The nomenclature of gangliosides. J Lipid Res 5:143-153.
110. Tagawa Y, Irie F, Hirabayashi Y, Yuki N. 1997. Cholinergic neuron-specific ganglioside GQ1b-alpha a possible target molecule for serum IgM antibodies in some patients with sensory ataxia. J Neuroimmunol 75:196-199.
111. Taguchi K, Utsunomiya I, Ren J, Yoshida N, Aoyagi H, Nakatani Y, Ariga T, Usuki S, Yu RK, Miyatake T. 2004a. Effect of rabbit anti-asialo-GM1 (GA1) polyclonal antibodies on neuromuscular transmission and acetylcholine-induced action potentials; neurophysiological and immunohistochemical studies. Neurochem Res 29:953-960.
112. Taguchi K, Ren J, Utsunomiya I, Aoyagi H, Fujita N, Ariga T, Miyatake T, Yoshino H. 2004b. Neurophysiological and immunobiological studies on Guillain-Barré syndrome with IgG anti-GalNAc-GD1a antibodies-effects on neuromuscular transmission. J Neurol Sci 225:91-98.
113. + currents in isolated rat myelinated nerve fibers. Ann Neurol 37:436-442.
114. + currents in rat single myelinated nerve fibers. Intern Med 39:123-127.
115. van der Meche FG. 1994. Intravenous immune globulin in the Guillain-Barré syndrome. Clin Exp Immunol 97:43-47.
116. van der Meche FG, Schmitz PI. 1992. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123-1129.
117. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. 1990. High-dose intravenous iminunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40:209-212.
118. Visser LH, van der Meche FGA, Meulstee J, Rothbarth PR, Jacobs BC, Schmitz PI, van Doorn PA. 1996. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical electrophisiologic, and prognostic features. Neurology 47:668-673.
119. Vriesendorp FJ. 1997. Insights into Campylobacter jejuni-induced Guillain-Barré syndrome from the Lewis rat model of experimental allergic neuritis. J Infect Dis 176:S164-S168.
120. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. 1993. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol 34:130-135.
121. Weber F, Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R. 1999. A small sodium channel blocking factor in the cerebrospinal fluid is preferentially found in Guillain-Barré syndrome: a combined cell physiological and HPLC study. J Neurol 246:955-960.
122. Weber F, Rudel R, Aulkemeyer P, Brinkmeier H. 2000. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve 23:1414-1420.
123. Weng NP, Yu-Lee LY, Sanz I, Patten BM, Marcus DM. 1992. Structure and specificities of anti-ganglioside autoantibodies associated with motor neuropathies. J Immunol 149:2518-2529.
124. Willison HJ. 2001. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of motor nerve terminal. Brain 124:893-906.
125. Willison HJ, Kennedy PG. 1993. Gangliosides and bacterial toxins in Guillain-Barré syndrome. J Neuroimmuol 46:105-112.
126. Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591-2625.
127. Willison HJ, Townson K, Veitch J, Boffey J, Isaacs N, Andersen SM, Zhang P, Ling CC, Bundle DR. 2004. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmunue neuropathy sera. Brain 127:680-691.
128. Wollinsky KH, Hulser PJ, Brinkmeier H, Mehrkens HH, Kornhuber HH, Rudel R. 1994. Filtration of cerebrospinal fluid in acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). Ann Med Intern 145:451-458.
129. Yamawaki M, Vasques A, Ben Younes A, Yoshino H, Kanda T, Ariga T, Baumann N, Yu RK. 1996. Sensitization of Lewis rats with sulfoglucuronosyl paragloboside: electrophysiological and immunological studies of an animal model of peripheral neuropathy. J Neurosci Res 44:58-65.
130. Yoshino H, Inuzuka T, Miyatake T. 1992. IgG antibody against GM1, GD1b and asialo-GM1 in chronic polyneuropathy following Mycoplasma pneumoniae infection. Eur Neurol 32:28-31.
131. Yoshino H, Harukawa H, Asano A. 2000. IgG anti-ganglioside antibodies in Guillain-Barré syndrome with bulbar palsy. J Neuroimminol 105:195-201.
132. Yu RK, Ariga T. 1998. The role of glycosphingolipids in neurological disorders. Mechanisms of immune action. Ann N Y Acad Sci 845:285-306.
133. Yu RK, Ariga T, Kohriyama T, Kusunoki S, Maeda Y, Miyatani N. 1990. Autoimmune mechanisms in peripheral neuropathies. Ann Neurol 27: S30-S35.
134. Yu RK, Saito M, Zhang Y, Fiorentini R, Khin-Maung-Gyi F, Friday GH. 1992. Analysis of serum anti-GM1 antibody titer in patients receiving GM1 therapy. Soc Neurosci Abstr 18:1472.
135. Yuki N. 1996. Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome. A new approach to treatment. Neurology 46:1644-1651.
136. Yuki N. 1997. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J Infect Dis 176:S150-S153.
137. Yuki N. 1998. Anti-ganglioside antibody and neuropathy: review of our research. J Periph Nerv Syst 3:3-18.
138. Yuki N, Ariga T. 1997. Antibodies to fucogangliosides in neurological diseases. J Neurol Sci 15:81-84.
139. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T. 1993. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771-1775.
140. Yuki N, Taki T, Takahashi M, Saito K, Yoshino H, Tai T, Handa S, Miyatake T. 1994. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 36:791-793.
141. Yuki N, Taki T, Handa S. 1996a. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Neuroimmunol 71:155-161.
142. Yuki N, Tagawa Y, Handa S. 1996b. Antibodies to peripheral nerve glycolipids SPG, SLPG and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polynruropathies. J Neuroimmunol 70:1-6.
143. Yuki N, Tagawa Y, Irie F, Hirabayashi Y, Handa S. 1997. Close association of Guillain-Barré syndrome with to minor monosialogangliosides GM1b and GM1alpha. J Neuroimmunol 74:30-34.
144. Yuki N, Ho TW, Tagawa Y, Koga M, Li CY, Hirata K, Griffin JW. 1999. Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J Neurol Sci 164:134-138.
145. Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, van der Meche FG. 2000. Clinical futures and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 47:314-321.
146. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hrata K. 2001. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49:712-720.
147. Yuki N, Suzuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M. 2004. Carbohydrate mimicry between human ganglioside GM1 and Campylobader jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 101:11404-11409.